Mitiglinide Calcium Suppliers and Product Information

Mitiglinide calcium is a non-sulfonylurea hypoglycemic agent used for the treatment of type 2 diabetes. It stimulates insulin secretion by closing ATP-sensitive potassium channels in pancreatic beta cells. This leads to depolarization, calcium influx, and subsequent insulin release. Mitiglinide has a rapid onset and short duration of action, which may help prevent hypoglycemia.

Frequently Asked Questions about Mitiglinide Calcium

Q: What is the mechanism of action of Mitiglinide?

A: Mitiglinide stimulates insulin secretion by closing ATP-sensitive potassium channels in pancreatic beta cells. This causes depolarization, calcium influx, and subsequent insulin release.

Q: How does Mitiglinide compare to sulfonylurea drugs?

A: Mitiglinide has a shorter duration of action compared to typical sulfonylurea agents. This characteristic may be advantageous in preventing hypoglycemia, a common adverse effect of sulfonylureas.

Q: What are the clinical benefits of Mitiglinide?

A: Clinical studies have shown that Mitiglinide significantly improves blood glucose control, including postprandial glucose and fasting plasma glucose levels. It has also demonstrated a low incidence of hypoglycemia, comparable to placebo.

Q: What is the typical dosage form of Mitiglinide?

A: Mitiglinide is typically available as Mitiglinide calcium, which is the calcium salt form of the drug.